

Oppenheimer 25th Annual Consumer Growth and E-Commerce Virtual Conference

Presented June 9, 2025

Safe Harbor Statements

Certain statements contained in this presentation are "forward-looking statements." We have tried to identify these forward-looking statements by using words such as "may," "might," " will," "expect," "anticipate," "believe," "could," " intend," "plan," "estimate," "should," "if," "project," and similar expressions. All statements other than statements of historical facts contained in this presentation, including statements regarding our mission, our strategic plan, our growth strategies, our vision, our market growth opportunity, our multi-year phased approach, our refranchising plans, our efforts to drive revenue growth, our 2025 guidance, prospects, plans, objectives of management and expected market growth and potential are forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. However, these forward-looking statements are subject to risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from our expectations and projections. Some of these risks, uncertainties and other factors are set forth in this presentation and in other documents we file with the United States Securities and Exchange Commission (the "SEC"). Given these risks and uncertainties, readers are cautioned not to place undue reliance on our forward-looking statements. Projections and other forward-looking statements included in this presentation have been prepared based on assumptions, which we believe to be reasonable, but not in accordance with U.S. Generally Accepted Accounting Principals ("GAAP") or any guidelines of the SEC. Actual results may vary, perhaps materially. You are strongly cautioned not to place undue reliance on such projections and other forward-looking statements. All subsequent written and oral forward-looking statements attributable us or to persons acting on our behalf are expressly gualified in their entirety by these cautionary statements. Except as required by federal securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Any such forward-looking statements, whether made in this presentation or elsewhere, should be considered in the context of the various disclosures made by us about our businesses including, without limitation, the risk factors discussed above.

Accounting Adjustments Related to the Consolidation of the Operations of the PCs

In those states which require a licensed Doctor of Chiropractic to own the entity that offers chiropractic services, the Company enters into a management agreement with a professional corporation (PC) licensed in that state to provide chiropractic services. To increase transparency into operating results and to align with accounting rules, the Company will now consolidate the full operations of the PC. This will result in increases to our revenue and G&A expenses by an identical amount and would have no impact on our bottom line except in instances when the PC has sold treatment packages and wellness plans. Revenue from these packages and plans will now be deferred and will be recognized when patients use their visits. The Company has previously consolidated its clinic operations in Non-PC states such as Arizona and New Mexico, and the deferred revenue around packages and plans in those states was already reflected in its financial statements. Therefore, these adjustments are isolated to the managed clinics in PC states. These adjustments will have no impact on cash flow.

Business Structure

The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington, West Virginia and Wyoming, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.



Our mission is to improve quality of life through routine and affordable chiropractic care.

Our vision is to build America's most accessible health and wellness services company.



Reasons to Join: Reasons to Invest Leading Chiropractic Care Franchise

Large & Growing Market

Category Leader & Creator

Attractive Asset-light Model

Strong Recurring Revenue

Cash Flow Positive, No Debt

New Strategic **Plan to** Strengthen Core and Reignite Growth



Consumer Problem Pain keeps people from living their best lives.

- 82% of new patients cite aches and pains as a reason for visiting
- 3rd most frequent cause for visiting a doctor is pain
- Pain is the leading cause of jobrelated disability and one of the top reasons people miss work.

Life, Unpaused 2025 Brand Campaign

With routine chiropractic care, individuals reclaim their ability to move freely and fully embrace life's experiences.







Providing Significant Advantages to our Patients

- Accessible via convenient retail locations
- Affordable at co-pay or lower prices
- No appointments or insurance needed
- Open evenings and weekends
- Membership model, geographically portable

Strong Operational KPIs

14.7M

adjustments in 2024

1.9M

unique patients treated in 2024

Up from 13.6M in 2023

Up from 1.7M in 2023

957K

new patients in 2024

Compared to 932K in 2023

36%

of new patients were new to chiropractic in 2024¹

~345K patients in 2024 had never been to a chiropractor before

85%

system-wide gross sales from monthly memberships in 2024

> Compared to 85% in 2023

¹ New patient survey completed early 2025.

Substantial Market Growth Opportunity: The Joint has ~6% of the Out-of-Pocket Share



1 IBIS September 2024 2 Kentley Insights Chiropractic Care Market Research Report February 2025 3 For the period ended Dec. 31, 2024

JYNT Sales ~2x Independent Collections



1 The FDDs 2023, 2022, 2021, 2020 and 2019

2 Chiro Eco Fees & Reimbursements Annual Surveys May 2024, June 2023, August 2022 and June 2021 (included 2020 and 2019 data).

NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved.

Top Franchise Recognition... Several Years Running





#1 Chiropractic Services Category



#37 of the

Top 500

TOP FRANCHISES SATISFACTION AWARD 2024



#38 of the Top 400, 6th year running, up from #150 in 2024 SUCCESS®

MAGAZINE One of the Top 50 Franchises

Large Market Opportunity



~1950 Potential Clinics

The Joint Patient Base

With usable addresses

- All 50 States, DC and Puerto Rico
- All Canadian Provinces and Territories
- 74 Countries on 6 Continents

Similar Points of Distribution

- Analyze demographics and psychographics
- Model attributes
- Roll across country

The Joint: First Mover Advantage

	Clinic Count at 3/31/25	Insurance	Private Pay
The Joint Corp. ¹	969		\checkmark
Airrosti	149	\checkmark	\checkmark
ChiroOne	101	\checkmark	
100% Chiropractic	88	\checkmark	\checkmark
Curis Functional Health (Previously The BackSpace)	41	\checkmark	
AlignLife Chiropractic	32	\checkmark	\checkmark
NuSpine	32		\checkmark
Chiropractic Company	21	\checkmark	\checkmark
Aligned Modern Health	18	\checkmark	\checkmark
ChiroWay	15	\checkmark	\checkmark
Chiropractic Partners	13		\checkmark
Chiro Now!	10	\checkmark	\checkmark
SnapCrack Chiropractic	9		\checkmark
Express Chiropractic	6		\checkmark
Affordable Chiropractic (Previously 20 Dollar Chiropractic)	4	\checkmark	✓
HealthSource Chiropractic	2	\checkmark	
Independent Offices. ²	38,438		

1 Franchises in 41 states, the District of Columbia and Puerto Rico | 2 Kentley 2024

Franchised Clinics 87% of Total Count

93% of corporate clinics signed LOIs to be refranchised as of May 8, 2025



Multi-year, Phased Approach

Strengthen Core & Become Pure Play Franchisor

2.0

Capture New Revenue through Additional Channels & Markets

3.0



Refranchising: Becoming a Pure Play Franchisor 93% of corporate clinics signed LOIs to be refranchised as of May 8, 2025

Vast Majority of Clinics in Final Stages of Letters of Intent Negotiations

• Marketing in 5 geographical regions:

Desert Region, SoCal, NorCal, Southeast & Kansas City

Goal: To Enhance Profitability Profile

- Generating capital
- Increasing franchise royalty and fees revenue
- Reducing corporate costs

Drive Revenue Growth

- Sharper Brand Positioning around Pain Relief
- Stronger Digital Marketing > Brand Awareness & Organic Leads
- New Dynamic Revenue Management
- Compelling Patient Facing Technology Upgrades
- Stronger Promotional Calendar





Strong Liquidity No Debt

\$ in Ms	3/31/25	12/31/24
Unrestricted cash	\$21.9	\$25.1
Restricted cash	\$1.0	\$0.9
Available JP Morgan Chase LOC ¹	\$20.0	\$20.0

Cash flow from operations:

- \$14.7M for 2023
- \$9.4M for 2024
- Expected to be positive for 2025

Federal tax return net operating loss carryforward was \$9.1M at Dec. 31, 2024

¹JPMorgan Chase LOC provides immediate access to \$20M through February 2027.

Reiterating 2025 Guidance

\$ in M	2024 Actual	2025 Low Guidance	2025 High Guidance			
System-wide sales ¹	\$530.3	\$530.3 \$550 \$570				
Comp sales for all clinics open 13 months or more ²	4%	Mid-single digits				
Consolidated Adjusted EBTIDA ³	\$11.4	\$10.0	\$11.5			
New franchised clinic openings excluding the impact of refranchised clinics	57	30	40			

1 System-wide sales include revenues at all clinics, whether operated or managed by is important the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information in understanding the company's financial performance, because these revenues are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. | 2 Comp sales include only the sales from clinics that have been open at least 13 or 48 full months and exclude any clinics that have permanently closed. | 3 The 2025 Consolidated Adjusted EBITDA estimate includes an adjustment of \$4.4 million related to, among other things, stock-based compensation and depreciation and amortization. The company will factor in any additional impairment or restructuring charges related to the refranchising should they be occurred.

Committed to Driving Success



APPENDIX

Growing National Footprint



Only 3.4% of Franchises Have 900+ Units

301-900 Units 5.6% 0-50 Units **68.1%** 101-300 Units 12.7% 51-100 Units 10.2%

> 900 Units = 3.4%

Percentage of Franchise Brands by # of Units

Strengthen Clinic Economics & Reignite Growth



• ~\$250k - \$275k initial build-out

Chart includes:

- 2% of gross sales for the National Marketing Fund
- Local marketing expenses, wages, rent and G&A expenses

Chart excludes:

- \$599 per month tech fee
- 7% royalty on gross sales
- \$39.9K per license, prior to year 1 sales
- Assumes breakeven monthly gross sales ¹ of \$31k - \$39k

1 Breakeven varies on a clinic-by-clinic basis based on actual gross sales and operating expenses. This represents operating income excluding income taxes and depreciation.

Robust Clinic Economics

System-wide Sales & Potential 4-Wall Clinic Contribution¹

(5 yr. avg., \$ in 000s) \$563 \$537 \$513 \$504 \$460 \$422 \$394 \$260^{\$277} \$152 **\$1**30 **\$1**09 \$115 \$53 **\$**97 \$72 \$24 Historical System Avg. Gross Sales (Jan-13 to Mar-25) Historical System Avg. Gross Sales (Jan-17 to Mar-25) \$(96) Operating Profit (Jan-13 to Mar-25) \$(114) Operating Profit (Jan-17 to Mar-25) Yr. 2 Yr. 1 Yr. 3 Yr. 4 Yr. 5

\$608



1 System-wide sales include revenues at all clinics, whether operated or managed by is important the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information in understanding the company's financial performance, because these revenues are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. | 2 Comp sales include only the sales from clinics that have been open at least 13 full months and exclude any clinics that have permanently closed.

Leading Market Growth

The Joint Corp. 14-yr. CAGR 54%¹ vs. Industry 5-yr. CAGR 5.1%²

People will continue to seek more noninvasive, holistic ways to manage their pain.

We'll be there to treat them.



1 For the period ended Dec. 31, 2024 2 March 2023 Kentley Insights Chiropractic Care Market Research Report

Q1 2025 Continuing Operations as of Mar. 31, 2025

\$ in M ¹	3 mos. 3/31/25	3 mos. 3/31/24	Differe	nces
Revenue	\$13.1	\$12.2	\$0.9	7%
Cost of revenue	3.0	2.7	0.3	10%
Sales and marketing	3.5	2.2	1.3	57%
Depreciation and amortization	0.4	0.3	0.1	10%
G&A	6.9	7.3	(0.4)	(6)%
Operating loss	(0.7)	(0.4)	(0.3)	NA
Other income	0.2	0.0	0.2	NA
Income tax expense	0.0	0.0	0.0	NA
Net loss from continuing operations ²	(0.5)	(0.4)	(0.1)	NA
Net income from discontinued operations ²	1.3	1.3	0.0	NA
Net income	0.8	0.9	(O.1)	NA
Adjusted EBITDA from continuing operations ³	0.0	0.4	(0.4)	NA
Adjusted EBITDA from discontinued operations ³	2.8	3.1	(0.3)	NA
Consolidated Adjusted EBITDA ³	2.9	3.5	(0.6)	NA

1 Due to rounding, numbers may not add up precisely to the totals. | 2 The results of the corporate clinic segment are reported in from discontinued operations and the franchised clinics in continued operations | 3 Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.

Board of Directors

Matthew E. Rubel Lead Director, 2017	Ronald V. DaVella, CPA Director, 2014	Suzanne M. Decker Director, 2017	Jeff CrammDirector, 2024	Christopher M. Grandpre Director, 2025	Abe Hong Director, 2018	Sanjiv Razdan Director, 2024
 Chair, Holley Inc. & Mid Ocean Ptrs. PE Consumer Group Former Exe. Chair KidKraft, Inc. Former Dir.: Hudson's Bay Co., HSNi & Treehouse Foods Former Mgmt: Roark Capital, TPG Capital, TPG Growth, Varsity Brands, Collective Brands, Cole Haan, J Crew, Popular Club Plan and more Pres. Appointee, House Advisory Council on Trade Policy Negotiation 	 Dir. & Chairman, Delta Dental of Arizona Partner & Financial Advisor, Industrial Succession Corp Financial Advisor, Universal Health Group Dir. Universal Health Group Former Mgmt or Dir.: Deloitte & Touche Mobile Holdings Properties Alkaline Water Co. NanoFlex Power Corp. Amazing Lash Studio Franchise 	 Director: Galen Mental Health & Lightwave Dental Consultant, Lindsay Goldberg Former Exe. Project Sponsor and former Chief HR Officer, Aspen Dental Mgmt Former Dir.: Refresh Mental Health Davis Vision Companies Former Advisor, Bond Veterinary 	 Partner & PM, Bandera Partners Chairman, Tandy Leather Factory Dir. Innovative Food Holdings Former Dir.: Rubicon Technology Ambassadors Group Morgan's Foods Peerless Systems 	 Chairman, Empower Brands Oper. Partner. & Exe. Board, MidOcean Partners Former Mgmt. or Dir. Outdoor Living Brands Inc. National Restorations (now Renovar) U.S. Structures National Guaranty Corporation Matrix Capital Markets Group 	 EVP & CTO, Learning Care Group Former Mgmt.: Discount Tire Company Red Rock Resorts Starbucks Corp. Technologent 	 CEO, Pres. & Dir., The Joint Corp. Former Dir., Bluestone Lane Former Mgmt.: The Coffee Bean & Tea Leaf Sweetgreen Applebee's YUM! Brands ITC Hotels
BS, Ohio University MBA, University of Miami	BS, Queens College MBA, Pace University	BS, Russell Sage College	BA, University of Chicago MBA, Columbia Business	BSBA, University of Notre Dame MBA, Virginia Commonwealth University	BE, U.S. Military Academy at West Point	BS, St. Xavier's College, Mumbai ITC Hotels Mgmt. Dev. Inst.

Executive Team

Sanjiv Razdan	Jake Singleton	Lori Abou Habib	Charles Nelles	Beth Gross	Craig Sherwood	Andra Terrell	Eric Wyatt	Dr. Steve Knauf
CEO, Pres. & Dir.	CFO	СМО	сто	SVP, HR	SVP, Development	SVP, Legal	SVP, Operations & Patient Experience	VP of Chiropractic & Compliance
 The Coffee Bean & Tea Leaf Sweetgreen Applebee's Yum! Brands ITC Hotels 	 EY American Institute of CPAs 	 SONIC® America's Drive- In®, part of the Inspire Brands CKE Restaurants, Inc. Eateries, Inc. 	 American Express Global Business Travel Western Union The Children's Hospital of Denver PacifiCare Health Systems 	 Spear Education Cranial Technologies The Grow Search Group Fresh Express Robert Half International 	 Lumin Fitness Wingstop Restaurants Little Caesars Pizza Gold's Gym SONIC® America's Drive- In®, part of the Inspire Brands Fazoli's Restaurant Corner Bakery Café Yum! Brands 	 Franchise World Headquarters (Subway) Regis Corporation Cajun Operating Company Luxottica Retail North America GNC Franchising Decorating Den Systems 	 Clean Eatz Norms Restaurant CKE Restaurants Boston Market Corporation Panera Bread L Brands Starbucks Corporation Taco Bell Mobil Oil 	 Arizona Board of Chiropractic Examiners Northwestern Health Sciences University International Chiropractors Assn. American Chiropractic Assn. Health Care Compliance Assn.
BS, St. Xavier's College, Mumbai, India ITC Hotels Management Developemnt Institute.	MA, Univ. of Arizona BS, Univ. of Arizona	MBA, Webster International Univ. BA, Univ. of Central Oklahoma	BA, Univ. of Phoenix, Certified PMP	BA, Arizona State University	JD, William Mitchell College of Law BA, St. Lawerence Univ.	JD, Howard University School of Law BS, John Hopkins University	BA, East Stroudsburg University	DC, Northwestern Health Sciences Univ. BS, Northwestern Health Sciences Univ.

Revolutionizing Access to Chiropractic Care

Features	Industry Problems	The Joint's Solutions
Affordability (per appointment)	\$76 Average ¹	\$36 Average for 2024
Convenient Locations	Medical Centers / Offices	Retail Locations
Multiple Locations	Limited Locations	969 Clinics
Walk-in / No Appointment	Appointments Required	No Appointments
Insurance / Caps / Co-pays	Yes	Private Pay
Inviting, Consumer-centric Design	Clinical	Approachable, Consumer Friendly
Service Hours	Limited / Inconsistent	Open 6-7 Days + Nights & Weekends ²
Average Patient Visits per Clinic	155 per week ¹	301 per week ³ for 2024

¹Chiropractic Economics, 2024 |²Hours vary by clinic |³Number includes multiple visits per patient

The Joint¹

Median Age	40.0 years
Generation Mix	
Gen Z	19%
Millennial	41%
Gen X	28%
Baby Boomer	12%
Gender	
Female	48%

¹Patients who visited The Joint Chiropractic in 2024.

Patient Demographics



Transformative Opportunity for Chiropractors

	Industry	The Joint
Annual Salary	Median \$76,530 ¹	Starting \$85,000 ²
Accessibility	 Appointments required Medical centers & offices Traditional office hours 	 No appointments necessary Clustered, high-visibility retail locations Open evenings + weekends³
Practice & Insurance	 Challenges of managing a business without support Difficulty attracting new patients Insurance hassles Slow payment cycle 	 Proprietary CRM and POS software Ongoing training and coaching Ability to perfect technique Less administration Higher patient focus Better cash flow

¹Bureau of Labor Statistics, U.S. Department of Labor, 2023

² Based on Joint Corp. company-owned or managed actual salaries |³ Hours vary by clinic

Performance Metrics and Non-GAAP Measures

This presentation includes commonly discussed performance metrics. System-wide sales include revenues at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company's financial performance, because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. Comp sales include the revenues from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.

This presentation includes non-GAAP financial measures. EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the company's underlying operating performance and operating trends. Reconciliation of historical net income/(loss) to EBITDA and Adjusted EBITDA is presented in the table below. The company defines EBITDA as net income/(loss) before net interest, tax expense, depreciation, and amortization expenses. The company defines Adjusted EBITDA as EBITDA before acquisition-related expenses (which includes contract termination costs associated with reacquired regional developer rights), net (gain)/loss on disposition or impairment, stock-based compensation expenses, costs related to restatement filings, restructuring costs, litigation expenses (consisting of legal and related fees for specific proceedings that arise outside of the ordinary course of our business) and other income related to employee retention credits.

EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the company's financial statements filed with the SEC.

Please refer to the reconciliations of non-GAAP financial measures to their GAAP equivalents located in this presentation. This presentation includes forwardlooking guidance for certain non-GAAP financial measures, including Adjusted EBITDA. These measures will differ from net income (loss), determined in accordance with GAAP, in ways similar to those described in the reconciliations at the end of this release. We are not able to provide, without unreasonable effort, guidance for net income (loss), determined in accordance with GAAP, or a reconciliation of guidance for Adjusted EBITDA to the most directly comparable GAAP measure because the Company is not able to predict with reasonable certainty the amount or nature of all items that will be included in net income (loss).

GAAP – Non-GAAP Reconciliation Q1 2025 vs. Q1 2024 by Category

	Three Months Ended March 31,											
				2025			2024					
		m ntinuing erations	D	om iscontinued perations		et perations		om ontinuing oerations	Di	om iscontinued perations		t perations
Non-GAAP Financial Data:												
(Loss) Income	\$	(506,021)	\$	1,307,451	\$	801,430	\$	(398,919)	\$	1,345,898	\$	946,979
Net interest		(185,917)		239		(185,678)		(36,259)		628		(35,63]
Depreciation and amortization expense		361,930		26,385		388,315		329,634		1,074,272	1	,403,90(
Income tax expense		13,404		103,412		116,816		8,582		170,345		178,927
EBITDA		(316,604)		1,437,487		1,120,883		(96,962)		2,591,143	2	2,494,18
Stock compensation expense		293,941				293,941		493,395				493,395
Net loss on disposition or impairment		1,973		1,299,724		1,301,697		275		361,828		362,103
Restructuring Costs		67,084		71,384		138,468		28,000		129,036		157,036
Adjusted EBITDA	\$	46,394	\$	2,808,595	\$2	2,854,989	\$	424,708	\$	3,082,007	\$3	,506,715

GAAP – Non-GAAP Reconciliation Quarterly Continuing Operations

	2025			2024		
	Q1	Q1	Q2	Q3	Q4	2024
Continuing Ops only						
Net (loss) income from continuing operations	(506,021)	(398,919)	(1,710,023)	(414,383)	986,413	(1,536,912)
Net interest	(185,917)	(36,259)	(80,471)	(83,828)	(79,729)	(280,287)
Depreciation and amortization expense	361,930	329,634	342,454	345,835	345,530	1,363,453
Income tax expense	13,404	8,582	11,169	5,391	37,000	62,142
EBITDA	(316,604)	(96,962)	(1,436,871)	(146,985)	1,289,214	(391,604)
Stock compensation expense	293,941	493,395	552,065	430,250	203,295	1,679,005
Acquisition related expenses	-	-	478,710		-	478,710
Net loss on disposition or impairment	1,973	275	662	3,581	10,124	14,642
Costs related to restatement filings	-	-	-	-	-	-
Restructuring Costs	67,084	28,000	25,000	(25,000)	579,231	607,231
Adjusted EBITDA from continuing operations	\$ 46,394	\$ 424,708	\$ (380,434)	\$ 261,846	\$ 2,081,864	\$ 2,387,984

GAAP – Non-GAAP Reconciliation Quarterly Discontinued Operations

	2025				2024		
	Q1		Q1	Q2	Q3	Q4	2024
Discontinued Ops only							
Net income (loss) from discontinued operations	1,30	7,451	1,345,898	(1,886,375)	(2,750,756)	(3,701,698)	(6,992,931)
Net interest		239	629	561	495	429	2,114
Depreciation and amortization expense	2	6,385	1,074,272	1,181,359	893,398	209,655	3,358,684
Income tax expense	10	3,412	170,345	167,153	57,194	(182,050)	212,642
EBITDA	1,43	37,487	2,591,144	(537,302)	(1,799,669)	(3,673,664)	(3,419,491)
Stock compensation expense		-	-	-	-	-	-
Acquisition related expenses		-	-	-	-	-	-
Net loss on disposition or impairment	1,29	9,724	361,828	1,434,658	3,801,637	4,841,844	10,439,967
Costs related to restatement filings		-	-	-	-	-	-
Restructuring Costs	7	1,384	129,035	119,240	178,182	68,640	495,097
Litigation expenses		-	-	1,490,000	(9,000)	-	1,481,000
Other income related to the ERC		-	-	-	-	-	-
Adjusted EBITDA from discontinued operations	\$ 2,80	8,595	\$3,082,007	\$ 2,506,596	\$ 2,171,150	\$ 1,236,820	\$ 8,996,573

GAAP – Non-GAAP Reconciliation Quarterly Consolidated Operations

	2025		2024				
		Q1	Q1	Q2	Q3	Q4	2024
Consolidated Operations							
Net income (loss)		801,430	946,979	(3,596,398)	(3,165,139)	(2,715,285)	(8,529,843)
Net interest		(185,678)	(35,630)	(79,910)	(83,333)	(79,300)	(278,173)
Depreciation and amortization expense		388,315	1,403,906	1,523,813	1,239,233	555,185	4,722,137
Income tax expense		116,816	178,927	178,322	62,585	(145,050)	274,784
EBITDA		1,120,883	2,494,182	(1,974,173)	(1,946,654)	(2,384,450)	(3,811,095)
Stock compensation expense		293,941	493,395	552,065	430,250	203,295	1,679,005
Acquisition related expenses		-	-	478,710	-	-	478,710
Net loss on disposition or impairment		1,301,697	362,103	1,435,320	3,805,218	4,851,968	10,454,609
Costs related to restatement filings		-	-	-	-	-	-
Restructuring Costs		138,468	157,035	144,240	153,182	647,871	1,102,328
Litigation expenses		-	-	1,490,000	(9,000)	-	1,481,000
Other income related to the ERC		-	-	-	-	-	-
Adjusted EBITDA	\$	2,854,989	\$3,506,715	\$ 2,126,162	\$ 2,432,996	\$ 3,318,684	\$11,384,557



Sanjiv Razdan, President & CEO sanjiv.razdan@thejoint.com

The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960



Jake Singleton, CFO jake.singleton@thejoint.com

The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960



Kirsten Chapman, LHA Investor Relations thejoint@lhai.com

LHA Investor Relations | 50 California Street, Suite 1500 | San Francisco, CA 94111| (415) 433-3777

